Review: Cancer‐Induced Autoimmunity in the Rheumatic Diseases

Shah, Ami A.; Casciola‐Rosen, Livia; Rosen, Antony

doi:10.1002/art.38928

Cited by 102 publications

(101 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, these patients had CD4 T cells that preferentially recognize the mutated epitopes in the POLR3A subunit, suggesting that their immune response may initially be directed against the mutation-associated neoepitope, thereby enabling a B-cell response to the wild-type antigen. These data strongly suggest a model of cancer-induced autoimmunity in which mutated autoantigens serve as immunogens that may initiate disease similar to what has been suggested with other paraneoplastic neurological disorders in which tumors are thought to drive autoimmunity (9,10). In those studies, two additional observations were made.…”

Section: Significancesupporting

confidence: 69%

“…These studies reveal a subset of patients with scleroderma with a reproducible, robust autoimmune signature that indicates a distinct subtype of the disease with an underlying cause that may differ from other forms of the disease. Furthermore, we suspect that this extensive epitope spreading may play a role in immune control of cancers in general (9).…”

Section: Significancementioning

confidence: 99%

See 1 more Smart Citation

Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer

Shah

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

View full text Add to dashboard Cite

Scleroderma is a chronic autoimmune rheumatic disease associated with widespread tissue fibrosis and vasculopathy. Approximately two-thirds of all patients with scleroderma present with three dominant autoantibody subsets. Here, we used a pair of complementary high-throughput methods for antibody epitope discovery to examine patients with scleroderma with or without known autoantibody specificities. We identified a specificity for the minor spliceosome complex containing RNA Binding Region (RNP1, RNA recognition motif) Containing 3 (RNPC3) that is found in patients with scleroderma without known specificities and is absent in unrelated autoimmune diseases. We found strong evidence for both intra- and intermolecular epitope spreading in patients with RNA polymerase III (POLR3) and the minor spliceosome specificities. Our results demonstrate the utility of these technologies in rapidly identifying antibodies that can serve as biomarkers of disease subsets in the evolving precision medicine era.

show abstract

Section: Significancesupporting

confidence: 69%

Section: Significancementioning

confidence: 99%

Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer

Shah

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

View full text Add to dashboard Cite

show abstract

“…This is exemplified by recent studies confirming the association between malignancy and SSc in some cases, 6 suggesting shared pathogenic factors or a link with autoimmunity. 7 Thus, SRC seems to develop mostly within three years of disease onset, but in later stage disease is very rare, suggesting that the majority of SSc cases may be protected from SRC. Pulmonary hypertension (PAH ) develops in 1-2% of SSc cases per year from three years of disease duration; this risk persists with prevalence at approximately 5% at 5 years, 10% at 10 years and 15% at 15 years.…”

Section: S59mentioning

confidence: 99%

Advances in pathogenesis and treatment of systemic sclerosis

Denton

2015

Clinical Medicine

View full text Add to dashboard Cite

Systemic sclerosis is the most severe disease within the scleroderma spectrum and is a major medical challenge with high mortality and morbidity. There have been advances in understanding of pathogenesis that refl ect the interplay between immune-infl ammatory processes and vasculopathy and fi brosis. It can be regarded as a disease of connective tissue repair and this leads to organ-based complications. However the aetiology and triggering events remain to be elucidated. Treatment is available for many aspects of the disease although the available therapies are not curative and some complications remain very challenging, especially non-lethal manifestations such as fatigue, calcinosis and anorectal dysfunction. Immunosuppression is now established as a benefi cial approach but balancing risk and benefi t is vital, especially for powerful approaches such as autologous stem cell transplantation.

show abstract

“…Recently, myositis specific autoantibodies (MSA) were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1γ) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancerassociated myositis (1). In this regard, we report herein the first case of anti-TIF1γ dermatomyositis secondary to a myelodysplastic syndrome (MDS).…”

mentioning

confidence: 93%

First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome

2017

View full text Add to dashboard Cite

SUMMARYInflammatory myopathies as para-neoplastic phenomena were first described by Sterz in 1916. Recently, myositis specific autoantibodies were described in cancer-associated myositis. Anti-transcription intermediary factor 1 gamma (anti-TIF1γ) antibodies have been found in both young adults affected by juvenile dermatomyositis and in elderly patients with cancer-associated myositis. In this regard, we report herein the first case of anti-TIF1γ dermatomyositis secondary to a myelodysplastic syndrome.

show abstract

Review: Cancer‐Induced Autoimmunity in the Rheumatic Diseases

Cited by 102 publications

References 66 publications

Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer

Systematic autoantigen analysis identifies a distinct subtype of scleroderma with coincident cancer

Advances in pathogenesis and treatment of systemic sclerosis

First report of anti-TIF1γ dermatomyositis in a patient with myelodysplastic syndrome

Contact Info

Product

Resources

About